Nano PharmaSolutions
Nano PharmaSolutions is a privately held, clinical-stage pharmaceutical nanotechnology company that licenses its solvent-free NanoTransformer® PVD platform to pharma partners and develops a proprietary CNS nasal-spray drug pipeline (NT-301 in Phase 1 for Parkinson's, plus NT-401 for ALS and NT-501 for TBI).
- Company typePrivate
- Founded2019
- HeadquartersSan Diego, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Nano PharmaSolutions does
Nano PharmaSolutions, Inc. is a privately held, clinical-stage pharmaceutical nanotechnology company founded in 2019 and headquartered in San Diego, California. The company develops and commercializes a patented physical vapor deposition (PVD) platform called NanoTransformer® that improves the solubility and bioavailability of poorly water-soluble active pharmaceutical ingredients (APIs) by nano-coating them onto hydrophilic excipients under ultra-high vacuum without solvents, lipids, or polymers. The resulting N-granule® intermediate can be formulated into oral, pulmonary, nasal, or other dosage forms.
The company monetizes through three complementary streams: (1) technology licensing and co-development partnerships with innovative and generic pharmaceutical companies seeking to enhance delivery of challenging APIs; (2) GMP contract manufacturing via a co-manufacturing agreement with CDMO Mikart, LLC at its Atlanta facility, where the NanoTransformer® system has been installed for clinical-scale production (1–10 kg batch sizes); and (3) proprietary drug development through its Nano-CNS™ nasal-to-brain delivery platform, with three candidates in the pipeline — NT-301 (apomorphine freebase powder nasal spray for Parkinson's OFF episodes, in Phase 1 with positive interim data announced September 2025), NT-401 (nasal spray for ALS dysphagia), and NT-501 (intranasal TBI therapeutic for military applications). Go-to-market is enterprise field sales targeting pharmaceutical R&D decision-makers, supported by presence at industry conferences (BIO, DCAT, IPAC-RS, LSINW), white paper distribution, and a Parkinson's Disease Advisory Board of four leading KOLs.
Nano PharmaSolutions firmographics
Firmographics- Name
- Nano PharmaSolutions
- Legal name
- Nano PharmaSolutions, Inc.
- Website
- https://nanopharmasolutions.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Nano PharmaSolutions is a privately held, clinical-stage pharmaceutical nanotechnology company that licenses its solvent-free NanoTransformer® PVD platform to pharma partners and develops a proprietary CNS nasal-spray drug pipeline (NT-301 in Phase 1 for Parkinson's, plus NT-401 for ALS and NT-501 for TBI).
- Ownership category
- akta.pro rank
Nano PharmaSolutions industry classification
Industry- Product category
- Pharmaceutical Nanotechnology
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Crystallization, Particle Engineering & Micronization Services (HLAGAHAJ)
- akta.pro secondary industries
- Formulation & Preclinical CMC Support (Nonclinical) (HLAGAFAL), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
Keywords
Where Nano PharmaSolutions is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Nano PharmaSolutions business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
Revenue model
- Technology Licensing: Licensing NanoTransformer® technology platform to pharmaceutical companies for enhancing delivery of challenging APIs. The company supports both innovative and generic pharmaceutical companies.
- Proprietary Drug Development: Developing own pipeline of CNS medicines (NT-301, NT-401, NT-501) targeting multibillion-dollar markets with significant unmet needs, with potential for out-licensing or commercialization.
- Co-development Partnerships: Collaborating with pharmaceutical companies for co-development projects, providing nanoformulation expertise and manufacturing capabilities through CDMO partnerships.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Nano PharmaSolutions product offering
Product offeringCore offering
Nano PharmaSolutions commercializes the patented NanoTransformer® platform, a physical vapor deposition (PVD) nanotechnology system that nano-coats active pharmaceutical ingredients onto hydrophilic excipients under ultra-high vacuum without solvents, lipids, or polymers. The resulting N-granule® intermediate improves solubility and bioavailability of poorly water-soluble drugs and can be formulated into oral, pulmonary, nasal, or other dosage forms. The company also develops its own drug pipeline (NT-301, NT-401, NT-501) and licenses the platform to pharmaceutical partners.
Product overview
Nano PharmaSolutions offers a unified product portfolio centered on its patented NanoTransformer® platform technology for improving drug solubility and bioavailability. The NanoTransformer® uses physical vapor deposition (PVD) to create N-granule®, a nanodrug-coated carrier excipient that can be formulated into various dosage forms. Building on this core technology, the company has developed the Nano-CNS® platform specifically for nasal spray delivery of CNS drugs, with a pipeline of three drug candidates: NT-301 (Parkinson's disease OFF episodes), NT-401 (ALS with dysphagia), and NT-501 (traumatic brain injury). The company operates through a co-manufacturing agreement with Mikart, LLC for GMP production.
Differentiator
Problem solved
Functional benefit
Brands
- NanoTransformer®: Patented nanodrug manufacturing platform using physical vapor deposition (PVD) to improve drug solubility and bioavailability without solvents or polymers.
- Nano-CNS™
- N-granule®
Quantifiable outcome
- Rapid absorption with Tmax ~20 minutes demonstrated in Phase 1 single ascending dose trials of NT-301
- +3 more outcomes
Companies that use Nano PharmaSolutions
Customer profileNamed customers4 records
Segments4 records
Nano PharmaSolutions technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Nano PharmaSolutions partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Mikart, LLCcoreComprehensive collaboration agreement with Mikart, a leading CDMO in Atlanta, GA, for manufacturing clinical trial materials using NanoTransformer® technology. Mikart provides GMP manufacturing capabilities at their Atlanta facility where NPS has installed the NanoTransformer™ system for clinical batch production at 1-10 kg scale. The partnership enables execution of complex nanoparticle formulations at GMP scale and accelerates development of breakthrough therapies.
- World Trade Center San Diego (WTCSD)coreExport accelerator partnership through MetroConnect VI cohort providing $5,000 grant for international trips, SYSTRAN translation software, STEP grant consulting, and trade mission facilitation. WTCSD supported NPS in Korea and Netherlands trade missions, connecting the company with investors and industry partners abroad.
- Economic Development Corporation (EDC) San DiegominorPartnership through Advancing San Diego internship program that helped NPS hire a San Diego State University biology student as a paid intern at no cost. The intern worked approximately 230 hours and was later hired as a full-time employee, providing lab support.
- Korean Health Industry Development Institute (KHIDI)minorCEO Dr. Kay Olmstead serves as Global Pharma Key Opinion Leader for KHIDI, supporting Korean health industry development and fostering international partnerships in the Korean market.
- Parkinson's Disease Advisory BoardcoreAdvisory board comprising leading neurologists: Dr. Robert Hauser (USF), Dr. Peter LeWitt (Wayne State/Henry Ford), Dr. Rajesh Pahwa (Kansas Medical Center), and Dr. Stuart Isaacson (Boca Raton). Provides expertise for NT-301 Parkinson's disease clinical program development.
Scale indicators7 records
Recent moves7 records
Expansion highlights2 records
Nano PharmaSolutions competitors and assessment
Company assessmentDirect peers
- Impel Pharmaceuticals: Focused on nasal drug-device combination products for CNS indications; Nano PharmaSolutions' CMO previously served as CMO at Impel, and the companies pursue overlapping intranasal delivery approaches.
- Acorda Therapeutics: Markets Inbrija, an inhaled apomorphine therapy for Parkinson's OFF episodes — the most direct competitive product to NT-301 — making Acorda the primary commercial benchmark for Nano PharmaSolutions' lead asset.
- Lyndra Therapeutics: Develops novel oral drug delivery platforms targeting long-acting and improved bioavailability; comparable as an early-stage platform company focused on reformulating existing molecules for better delivery profiles.
- Neurelis: Develops intranasal drug-device therapies for CNS conditions including seizure rescue (Valtoco); highly comparable given the intranasal CNS delivery overlap with Nano-CNS™ and NT-301.
- Particle Sciences (Lubrizol): CDMO specializing in nanoformulation, particle engineering, and bioavailability enhancement — directly comparable services to NanoTransformer® for poorly soluble drugs.
- Ascendia Pharma: Specialty CDMO offering nanoemulsion, nanosuspension, and other nanoformulation services for poorly soluble APIs — a direct peer in the nanoformulation services market.
Broad incumbents
- Bend Research / Lonza: Established particle engineering and bioavailability CDMO within Lonza, providing spray-dried dispersions and solubility solutions; competes broadly in the same enablement space as NanoTransformer® but at significantly larger scale.
- Catalent: Global CDMO offering broad formulation, bioavailability, and nasal/inhalation drug delivery capabilities; overlaps with Nano PharmaSolutions in solubility enhancement and nasal CNS delivery as part of a much wider portfolio.
- Adare Pharmaceuticals (Laxxon): Specialty pharma/CDMO focused on drug delivery, bioavailability enhancement, and modified release technologies; competes broadly with the NanoTransformer® value proposition across multiple dosage forms.
Others
- Civitas Therapeutics (acquired by Acorda): Acquired by Acorda for its inhaled apomorphine ARCUS technology (now Inbrija); relevant precedent for inhaled/intranasal Parkinson's delivery that informs the NT-301 competitive landscape.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Nano PharmaSolutions social profiles
Digital presenceNano PharmaSolutions financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nano PharmaSolutions leadership team
Management profileNumber of profiles
Nano PharmaSolutions funding detail
Funding detailFunding overview
Funding rounds4 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nano PharmaSolutions M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nano PharmaSolutions
What does Nano PharmaSolutions do?
Nano PharmaSolutions commercializes the patented NanoTransformer® platform, a physical vapor deposition (PVD) nanotechnology system that nano-coats active pharmaceutical ingredients onto hydrophilic excipients under ultra-high vacuum without solvents, lipids, or polymers. The resulting N-granule® intermediate improves solubility and bioavailability of poorly water-soluble drugs and can be formulated into oral, pulmonary, nasal, or other dosage forms. The company also develops its own drug pipeline (NT-301, NT-401, NT-501) and licenses the platform to pharmaceutical partners.
Is Nano PharmaSolutions a public or private company?
Nano PharmaSolutions is a private company. It is currently operating.
When was Nano PharmaSolutions founded?
Nano PharmaSolutions was founded in 2019. It employs 1 to 10 people.
Where is Nano PharmaSolutions based?
Nano PharmaSolutions is headquartered in San Diego, United States, in the North America region.
How does Nano PharmaSolutions make money?
Three revenue lines are on record. Technology Licensing is the primary driver. The others are proprietary Drug Development and co-development Partnerships.
Who are Nano PharmaSolutions's main competitors?
Direct peers on record are Impel Pharmaceuticals, Acorda Therapeutics, Lyndra Therapeutics, Neurelis, Particle Sciences (Lubrizol) and Ascendia Pharma. Broad incumbents are Bend Research / Lonza, Catalent and Adare Pharmaceuticals (Laxxon). Civitas Therapeutics (acquired by Acorda) is listed as an others.
Does Nano PharmaSolutions have an API?
No public API is recorded for Nano PharmaSolutions.
What industry is Nano PharmaSolutions in?
Nano PharmaSolutions's product category is Pharmaceutical Nanotechnology. Its primary akta.pro industry code is HLAGAHAJ, Crystallization, Particle Engineering & Micronization Services, with a secondary code of HLAGAFAL, Formulation & Preclinical CMC Support (Nonclinical). Its NAICS code is 32541 and its SIC code is 2834.